Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US
MANAMA, Kingdom of Bahrain, Feb. 16, 2025 (GLOBE NEWSWIRE) -- The Bahrain…
New York Blood Center Enterprises Researchers Identify New Immune Response Mechanisms in Sickle Cell Disease
February 12, 2025 09:00 ET | Source: New York Blood Center Enterprises…
Bio X Cell Expands Global Reach with New Distribution Center in Beijing, China
LEBANON, N.H., Feb. 11, 2025 /PRNewswire/ -- Bio X Cell, the world's…
MaxCyte Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
January 30, 2025 02:00 ET | Source: MaxCyte, Inc ROCKVILLE, Md., Jan.…
Adjuvant Libtayo (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
Primary endpoint of DFS met at first prespecified interim analysis, showing a…
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Application based on TROPION-Lung05 phase 2 trial and supported by data from…
TVCMALL: Leading Cell Phone Accessories Wholesaler Boosts Your Online Sales at CES 2025
Las Vegas, NV, Jan. 10, 2025 (GLOBE NEWSWIRE) -- CES 2025, one…
Stem Health Plus Revolutionizes Skin Regeneration with Advanced Stem Cell Skin Graft Technology
CHICAGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Stem Health Plus, a leader…
European Commission approves RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line…
Research by City of Hope and Other Scientists May Help Patients Overcome Resistance to Chimeric Antigen Receptor (CAR) T Cell Therapy
Research on New System Published in Nature Biomedical Engineering Platform Engineers T…